We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma.
- Authors
PORKERT, Stefanie; MAI, Pamela; JONAK, Constanze; WEIHSENGRUBER, Felix; RAPPERSBERGER, Klemens; BAUER, Wolfgang; SIMONITSCH-KLUPP, Ingrid; RADERER, Markus; VALENCAK, Julia
- Abstract
Systemic monotherapy with rituximab is a well-known treatment approach for primary cutaneous follicle centre lymphoma and primary cutaneous marginal zone lymphoma. Both have excellent prognosis despite high relapse rates. To investigate the long-term effectiveness and clinical outcome of intravenous rituximab at a dose of 375 mg/m² once weekly, data for 26 patients (17 primary cutaneous follicle centre lymphoma and 9 primary cutaneous marginal zone lymphoma) were analysed retrospectively. Complete remissions occurred in 20 (77%) and partial remissions in 6 patients (23%), demonstrating an overall response rate of 100%. The relapse rate was 52.9% in primary cutaneous follicle centre lymphoma and 88.9% in primary cutaneous marginal zone lymphoma. Ongoing complete remissions after therapy with rituximab were observed in 9 patients (34.6%) with a median progression- free survival of 161 months (13.4 years). These results confirm that intravenous rituximab is an effective and well-tolerated treatment with durable responses in a relevant percentage of patients at a median follow-up of 148 months (12.3 years).
- Subjects
CUTANEOUS T-cell lymphoma; RITUXIMAB; LYMPHOMAS; TREATMENT effectiveness; RADIOSURGERY
- Publication
Acta Dermato-Venereologica, 2021, Vol 101, Issue 2, p1
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-3746